ReviewCurrent oncology (Toronto, Ont.)2021
Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Review in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis.The oncologist · 2026Article
- A nomogram predicting prognosis of extensive-stage small cell lung cancer patients receiving chemoradiotherapy.Radiation oncology (London, England) · 2025Article
- Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study.Journal of immunotherapy and precision oncology · 2025Article
- Effectiveness of Atezolizumab in Addition to Chemotherapy in ES-SCLC: A Retrospective Real-World Monocentric Study.Cancers · 2025Article
- Association of Erythrocyte-Related Indices with Immune-Related Adverse Events and Survival of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.The oncologist · 2025Article
- Review
- Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study.Current oncology (Toronto, Ont.) · 2024Article
- Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposideTranslational cancer research · 2024Article
- Immunotherapy for small cell lung cancer: the current state and future trajectories.Discover oncology · 2024Review
- Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer.Genomics, proteomics & bioinformatics · 2024Article
- Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report.Current oncology (Toronto, Ont.) · 2024Article
- Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy.Scientific reports · 2024Article
- Current dilemma and future directions over prophylactic cranial irradiation in SCLC: a systematic review in MRI and immunotherapy era.Frontiers in oncology · 2024Review
- Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment.ImmunoTargets and therapy · 2024Article
- Review
- Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.Frontiers in oncology · 2023Article
- Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy.Cancer management and research · 2023Article
- External Validation of the Graded Prognostic Assessment in Patients with Brain Metastases from Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) remains a poorly understood disease with aggressive features, high relapse rates, and significant morbidity as well as mortality, yet persistently limited treatment options. For three decades, the treatment algorithm of SCLC has been stagnant despite multiple attempts to find alternative therapeutic options that could improve responses and increase survival rates. On the other hand, immunotherapy has been a thriving concept that revolutionized treatment options in multiple malignancies, rendering previously untreatable diseases potentially curable. In extensive stage SCLC, immunotherapy significantly altered the course of disease and is now part of the treatment algorithm in the first-line setting. Nevertheless, the important questions that arise are how best to implement immunotherapy, who would benefit the most, and finally, how to enhance responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.